| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $389.0M | — | +260.2% |
| Cost of Revenue | $955.0M | — | +961.1% |
| R&D Expense | $649.0M | — | -24.2% |
| SG&A Expense | $173.0M | — | -18.4% |
| Operating Income | -$1.39B | — | -32.2% |
| Pre-tax Income | -$1.33B | — | -38.4% |
| Income Tax | $9.0M | — | +28.6% |
| Net Income | -$1.34B | — | -38.3% |
| EPS (Basic) | -$3.40 | — | -34.9% |
| EPS (Diluted) | -$3.40 | — | -34.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $1.91B | -26.5% | +17.6% |
| Accounts Receivable | $71.0M | -61.4% | -9.0% |
| Inventory | $146.0M | -4.6% | +14.1% |
| Current Assets | $5.77B | -11.8% | -14.7% |
| Total Assets | $11.49B | -6.9% | -9.6% |
| Current Liabilities | $2.40B |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$630.0M | — | +39.2% |
| Capital Expenditures | $62.0M | — | -47.0% |
| Investing Cash Flow | -$76.0M | — | -110.4% |
| Financing Cash Flow | $17.0M | — | +325.0% |
| Free Cash Flow | -$692.0M | — | +40.0% |
| +49.3% |
| Long-term Debt | $590.0M | +0.0% | — |
| Total Liabilities | $4.08B | +10.6% | +54.7% |
| Stockholders' Equity | $7.41B | -14.4% | -26.4% |